Literature DB >> 10556281

Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9.

M Niksic1, M Romano, E Buratti, F Pagani, F E Baralle.   

Abstract

The rate of exon 9 exclusion from the cystic fibrosis transmembrane conductance regulator (CFTR) mRNA is associated with monosymptomatic forms of cystic fibrosis. Exon 9 alternative splicing is modulated by a polymorphic polythymidine tract within its 3' splice site. We have generated a minigene carrying human CFTR exon 9 with its flanking intronic sequences and set up an in vivo model to study the cis-acting DNA elements which modulate its splicing. Transfections into human cell lines showed that T5, but not T9 or T7 alleles, significantly increases the alternative splicing of exon 9. Moreover, we found that another polymorphic locus juxtaposed upstream of the T tract, and constituted by (TG)(n)repeats, can further modulate exon 9 skipping but only when activated by the T5 allele. Then, we extended our studies to the mouse CFTR exon 9 which does not show alternative splicing. Comparison of human and mouse introns 8 and 9 revealed a low homology between the two sequences and the absence of the human polymorphic loci within the mouse intron 3' splice site. We have tested a series of constructs where the whole human exon 9 with its flanking intronic sequences was replaced partially or completely by the murine counterpart. The transfections of these constructs in human and murine cell lines reveal that also sequences of the downstream intron 9 affect exon 9 definition and co-modulate, with the UG/U 3' splice site sequences, the extent of exon 9 skipping in CFTR mRNA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556281     DOI: 10.1093/hmg/8.13.2339

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  34 in total

1.  Long-range (17.7 kb) allele-specific polymerase chain reaction method for direct haplotyping of R117H and IVS-8 mutations of the cystic fibrosis transmembrane regulator gene.

Authors:  Genevieve Pont-Kingdon; Mohamed Jama; Christine Miller; Alison Millson; Elaine Lyon
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

2.  Splicing of constitutive upstream introns is essential for the recognition of intra-exonic suboptimal splice sites in the thrombopoietin gene.

Authors:  M Romano; R Marcucci; F E Baralle
Journal:  Nucleic Acids Res       Date:  2001-02-15       Impact factor: 16.971

3.  Identification of putative new splicing targets for ETR-3 using sequences identified by systematic evolution of ligands by exponential enrichment.

Authors:  Nuno André Faustino; Thomas A Cooper
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

4.  Intron-mediated alternative splicing of Arabidopsis P5CS1 and its association with natural variation in proline and climate adaptation.

Authors:  Ravi Kesari; Jesse R Lasky; Joji Grace Villamor; David L Des Marais; Ying-Jiun C Chen; Tzu-Wen Liu; Wendar Lin; Thomas E Juenger; Paul E Verslues
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

Review 5.  Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling.

Authors:  D A S de Souza; F R Faucz; L Pereira-Ferrari; V S Sotomaior; S Raskin
Journal:  Andrology       Date:  2017-12-07       Impact factor: 3.842

6.  Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign.

Authors:  Joshua D Groman; Timothy W Hefferon; Teresa Casals; Lluís Bassas; Xavier Estivill; Marie Des Georges; Caroline Guittard; Monika Koudova; M Daniele Fallin; Krisztina Nemeth; Gyorgy Fekete; Ludovit Kadasi; Ken Friedman; Martin Schwarz; Cristina Bombieri; Pier Franco Pignatti; Emmanuel Kanavakis; Maria Tzetis; Marianne Schwartz; Giuseppe Novelli; Maria Rosaria D'Apice; Agnieszka Sobczynska-Tomaszewska; Jerzy Bal; Manfred Stuhrmann; Milan Macek; Mireille Claustres; Garry R Cutting
Journal:  Am J Hum Genet       Date:  2003-12-18       Impact factor: 11.025

Review 7.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

8.  The CFTR polymorphisms poly-T, TG-repeats and M470V in Chinese males with congenital bilateral absence of the vas deferens.

Authors:  Wu-Hua Ni; Lei Jiang; Qian-Jin Fei; Jian-Yuan Jin; Xu Yang; Xue-Feng Huang
Journal:  Asian J Androl       Date:  2012-07-30       Impact factor: 3.285

9.  Alternative splicing of the ovine CFTR gene.

Authors:  Fiona C Broackes-Carter; Sarah H Williams; Pei Ling Wong; Nathalie Mouchel; Ann Harris
Journal:  Mamm Genome       Date:  2003-11       Impact factor: 2.957

10.  Assessing the Disease-Liability of Mutations in CFTR.

Authors:  Claude Ferec; Garry R Cutting
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.